Zai Lab (ZLAB) Set to Announce Quarterly Earnings on Wednesday

Zai Lab (NASDAQ:ZLAB) will announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.11). The firm had revenue of $65.83 million for the quarter, compared to analysts’ expectations of $70.41 million. Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

ZLAB stock opened at $15.80 on Wednesday. The firm has a market cap of $1.57 billion, a PE ratio of -4.58 and a beta of 1.10. The firm’s 50 day moving average price is $17.29 and its 200-day moving average price is $22.44. Zai Lab has a one year low of $13.48 and a one year high of $39.50.

Analysts Set New Price Targets

ZLAB has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a report on Friday, January 12th. Citigroup dropped their target price on shares of Zai Lab from $123.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $64.22.

Insider Activity at Zai Lab

In other Zai Lab news, insider Joshua L. Smiley sold 1,988 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total value of $31,151.96. Following the completion of the transaction, the insider now owns 28,684 shares in the company, valued at $449,478.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Zai Lab news, CEO Ying Du sold 5,787 shares of the business’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $16.15, for a total value of $93,460.05. Following the completion of the transaction, the chief executive officer now owns 1,107,972 shares in the company, valued at $17,893,747.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Joshua L. Smiley sold 1,988 shares of the business’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the completion of the transaction, the insider now owns 28,684 shares of the company’s stock, valued at approximately $449,478.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,568 shares of company stock worth $208,508. Insiders own 5.23% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.